A Phase 3 clinical trial of lanreotide was listed as recruiting as of November 6, 2026. The study, titled "Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula," is registered under identifier NCT06807437.
According to the listing, the trial compares lanreotide to placebo when given before surgery. The stated purpose is to examine prevention of a surgical complication known as a pancreatic fistula. The trial is currently in Phase 3 and its status is recruiting.
No results have been posted for this trial as of the listed date. The event data does not include enrollment numbers, specific surgical procedures, or outcome measures beyond the trial title. This brief reflects only the status update as recorded on ClinicalTrials.gov and does not characterize any findings, since none have been reported.
Readers interested in lanreotide's approved uses and background can consult the compound overview for additional context.